Rebetol is owned by Schering.
Rebetol contains Ribavirin.
Rebetol has a total of 2 drug patents out of which 0 drug patents have expired.
Rebetol was authorised for market use on 29 July, 2003.
Rebetol is available in solution;oral dosage forms.
The generics of Rebetol are possible to be released after 05 October, 2023.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6790837||SCHERING||Ribavirin syrup formulations|| |
(2 months from now)
|SCHERING||Ribavirin syrup formulations|| |
(8 months from now)
Market Authorisation Date: 29 July, 2003
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic